A detailed history of Perceptive Advisors LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Perceptive Advisors LLC holds 600,000 shares of RVNC stock, worth $1.54 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
600,000
Holding current value
$1.54 Million
% of portfolio
0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.65 - $9.31 $2.79 Million - $5.59 Million
600,000 New
600,000 $2.95 Million
Q4 2022

Feb 14, 2023

SELL
$18.32 - $30.66 $1.46 Million - $2.44 Million
-79,574 Reduced 9.84%
729,097 $13.5 Million
Q3 2022

Nov 14, 2022

BUY
$14.33 - $28.47 $3.38 Million - $6.72 Million
236,157 Added 41.25%
808,671 $21.8 Million
Q2 2022

Aug 15, 2022

BUY
$11.52 - $20.4 $5.01 Million - $8.87 Million
435,000 Added 316.33%
572,514 $7.91 Million
Q1 2022

May 16, 2022

BUY
$12.36 - $20.31 $1.7 Million - $2.79 Million
137,514 New
137,514 $2.68 Million
Q3 2020

Nov 16, 2020

SELL
$23.23 - $34.3 $1.53 Million - $2.26 Million
-65,839 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$12.6 - $26.55 $10.8 Million - $22.8 Million
-859,161 Reduced 92.88%
65,839 $1.61 Million
Q1 2020

May 15, 2020

BUY
$12.46 - $27.81 $1.3 Million - $2.91 Million
104,623 Added 12.75%
925,000 $13.7 Million
Q4 2019

Feb 14, 2020

BUY
$11.66 - $20.15 $9.57 Million - $16.5 Million
820,377 New
820,377 $13.3 Million
Q2 2018

Aug 14, 2018

SELL
$27.45 - $33.35 $17 Million - $20.6 Million
-618,957 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$29.15 - $37.4 $6.38 Million - $8.19 Million
218,957 Added 54.74%
618,957 $19.1 Million
Q4 2017

Feb 14, 2018

BUY
$24.55 - $36.3 $9.82 Million - $14.5 Million
400,000
400,000 $14.3 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.